Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05642858

Text Education About Cardiovascular Health and HIV (TEACH-HIV)

The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

HIV Acquired Immunodeficiency Syndrome Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Blood-Borne Infections Cardiovascular Diseases Communicable Diseases Genital Diseases HIV Infections Human Immunodeficiency Virus Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Urogenital Diseases Vascular Diseases Virus Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California San Francisco, San Francisco, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HIV positive
  • At least 40 years of age
  • English-speaking

Exclusion criteria

  • Existing clinical atherosclerotic cardiovascular disease (ASCVD)
  • Pregnant
  • Unwilling/unable to provide informed consent
  • Does not own a smartphone

Treatment and study plan

Digital Educational Messaging

Behavioral

Education via mobile phone text messages for up to 6 months.

Primary outcomes

  1. Proportion of participants with controlled blood pressure

    Time frame: 6 months

    Proportion of participants with blood pressure < 130/80 mmHg as recorded in the electronic health record (EHR).

Secondary outcomes

  1. Number of cardiovascular risk factors controlled

    Time frame: 6 months

    Total of 8 risk factors: diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids, blood glucose, blood pressure. Risk factors will be assessed using self-report and EHR data. Risk factor control will be defined based on the American Heart Association's (AHA) Life's Essential 8.

  2. Self-perceived cardiovascular risk

    Time frame: 6 months

    Measured by self-report using questions adapted from the patient and provider assessment of lipid management (PALM) registry.

  3. Systolic blood pressure

    Time frame: 6 months

    Evaluated using EHR data.

  4. Cholesterol

    Time frame: 6 months

    Non-HDL cholesterol, total cholesterol, LDL cholesterol (in mg/dL), as evaluated using EHR data.

  5. Physical activity

    Time frame: 6 months

    Minutes/week, measured via self-report using the International Physical Activity Questionnaire (IPAQ).

  6. Physical activity

    Time frame: 6 months

    Measured via step count.

  7. Mediterranean diet

    Time frame: 6 months

    Measured using the Mediterranean Eating Pattern for Americans (MEPA) tool, as scored by AHA's Life's Essential 8. Score ranges 0-16, with higher scores representing better outcomes.

  8. Proportion of current smokers

    Time frame: 6 months

    Measured via self-report.

  9. Blood sugar control

    Time frame: 6 months

    Evaluated using EHR data on hemoglobin A1c and fasting blood glucose. Blood sugar control will be defined based on the AHA's Life's Essential 8 definitions.

  10. Body mass index

    Time frame: 6 months

    Evaluated in kg/m2 using EHR data.

  11. Proportion of patients on guideline-based therapy

    Time frame: 6 months

    Proportion of patients on anti-hypertensive medications, statins, and aspirin, among those who meet criteria for therapy based on American Heart Association / American College of Cardiology (AHA/ACC) guidelines.

Study contacts

Contact information is provided by the study sponsor or research team.

Megan McLaughlin, MD, MPH

CONTACT

[email protected]

628-206-8037

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Dec 8, 2022
Registry last updated
Jun 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.